2Carbon C.Comparison of side effects of levofloxacin versus other fluoroquinolones[J].Chemotherapy,2001,47(3):9-9.
3JLM. Oral and iv formulations of gatifoxacin cleared for US. market. Am J Health-Syst Pharm, 2000; 57:204
4Hosaka M, Kinoshita S, Toyama A, et al. Antibacterial properties of AM-1155, a new 8-methoxy quinolone. J Antimicrob Chemther,1995; 36:293
5Tomioka H, Saito H, Sato K. Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin and ofloxacin. Antimicrob Agents Chemother, 1993;37:1259
6Takei M, Fukuda H, Yasue T, et al. Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian typeⅡ topoisomerase. Antimicro Agents Chemother, 1998;42:2678
7Wakabayshi E, Mitsuhashi S. In vitro antibacterial activitiy of AM-1155, a novel 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother, 1994;38:594
8Fukuda H, Hori S, Hiramatsu K. Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone- resistants mutants and the norA transformant of staphylococcus aureus. Antimicrob Agents Chemother, 1998;42:1917
9Deguchi T, Yasuda M, Nakano M, et al. Comparision of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. Chemotherapy, 1997;43:239
10Appelbaum PC. Quinolone activity against anaerobes. Drugs, 1999;58 (suppl 2):60
